PRPH
ProPhase Labs, Inc. NASDAQ Listed Apr 4, 1994$0.08
+0.00%
vs $0.08
Mkt Cap $369.5K
52w Low $0.07
0.1% of range
52w High $6.70
50d MA $0.11
200d MA $1.40
P/E (TTM)
—
EV/EBITDA
—
P/B
0.0x
Debt/Equity
3.3x
ROE
-781.5%
P/FCF
-0.0x
RSI (14)
29.40
ATR (14)
$0.02
Beta
-0.32
50d MA
$0.11
200d MA
$1.40
Avg Volume
46.2K
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
711 Stewart Avenue · Garden City, NY 11530 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | AMC | -1.20 | -0.87 | +27.5% | — | — | — | — | — | — | — | — |
| Jun 16, 2026 | AMC | -1.20 | -0.87 | +27.5% | 0.08 | -6.1% | -6.2% | +0.0% | +0.0% | — | — | — |
| Jun 11, 2026 | AMC | -1.20 | -0.87 | +27.5% | 0.09 | +5.6% | -11.1% | +12.5% | -11.1% | +0.0% | +0.0% | — |
| Jun 9, 2026 | AMC | -1.20 | -0.87 | +27.5% | 0.10 | +0.0% | -0.2% | -10.0% | -11.1% | +12.5% | -11.1% | — |
| Jun 4, 2026 | AMC | -1.20 | -0.87 | +27.5% | 0.13 | -15.4% | -15.4% | -9.1% | +0.0% | +0.0% | -10.0% | — |
| Nov 19, 2025 | AMC | -1.10 | -1.60 | -45.5% | 2.34 | -0.9% | -17.9% | -1.6% | -4.8% | +0.0% | +0.6% | — |
| Aug 13, 2025 | AMC | -0.15 | -0.11 | +26.7% | 3.27 | -3.7% | +1.8% | +4.8% | -4.3% | -6.3% | +5.4% | — |
| May 20, 2025 | AMC | -0.18 | -0.12 | +33.3% | 3.28 | +2.4% | -12.5% | +7.0% | +4.2% | +12.5% | -2.8% | — |
| Mar 31, 2025 | AMC | -0.24 | -0.51 | -112.5% | 4.04 | -3.0% | +0.0% | -3.5% | -11.3% | -30.6% | +12.9% | — |
| Nov 13, 2024 | AMC | -0.31 | -0.35 | -12.9% | 7.70 | -1.3% | -2.5% | -0.1% | +4.9% | -3.4% | +0.7% | — |
| Aug 14, 2024 | AMC | -0.08 | -0.33 | -312.5% | 12.50 | -2.4% | -9.6% | +10.6% | +17.6% | -2.7% | -0.7% | — |
| May 9, 2024 | AMC | -0.28 | -0.07 | +75.0% | 24.60 | +0.8% | +2.8% | +4.7% | -4.2% | +1.2% | -0.4% | — |
| Mar 28, 2024 | AMC | -0.26 | -0.51 | -96.2% | 32.40 | +1.9% | +5.9% | +0.6% | -4.1% | -0.6% | +3.3% | — |
| Mar 15, 2024 | AMC | -2.60 | -5.10 | -96.2% | 24.30 | -7.8% | +3.7% | +2.0% | +1.9% | +5.7% | +1.4% | — |
| Nov 9, 2023 | AMC | -0.20 | -0.30 | -50.0% | 25.50 | -2.0% | -10.6% | -0.4% | -4.4% | +0.0% | +0.5% | — |
| Aug 10, 2023 | AMC | -0.14 | -0.20 | -42.9% | 31.50 | +1.3% | -2.2% | -6.2% | -1.4% | -1.8% | -3.6% | — |
| May 11, 2023 | AMC | -0.10 | 0.03 | +130.0% | 42.50 | -0.7% | -6.6% | +1.3% | +8.7% | +1.4% | -4.3% | — |
| Mar 28, 2023 | AMC | -0.01 | -0.08 | -579.9% | 41.40 | -0.5% | -6.3% | -3.9% | +2.1% | +3.1% | -2.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.80 | $25.50 | +2.8% | +0.0% | +0.0% | +0.0% | +2.4% | -0.8% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.50 | $25.00 | -2.0% | -10.6% | -0.4% | -4.4% | +0.0% | +0.5% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.80 | $30.30 | -1.6% | -6.2% | -1.4% | -1.8% | -3.6% | -4.1% |
| Jun 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.80 | $45.60 | -0.4% | -6.3% | -5.4% | +2.0% | +1.0% | -2.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.50 | $42.20 | -0.7% | -6.6% | +1.3% | +8.7% | +1.4% | -4.3% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.30 | $36.80 | +1.4% | -1.9% | -3.4% | -3.8% | +3.3% | +5.8% |
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.30 | $38.30 | +2.7% | -1.1% | -2.4% | +0.8% | +0.8% | +1.1% |
| Feb 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.10 | $39.00 | -2.7% | -4.7% | +2.9% | -0.8% | -4.4% | -1.1% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.50 | $39.50 | +0.0% | +4.1% | -1.0% | -1.2% | +2.5% | -0.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.30 | $59.00 | +4.8% | +7.1% | -0.8% | -1.2% | -0.5% | +4.4% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.00 | $38.70 | +1.8% | +0.8% | +0.3% | +1.6% | -1.3% | +10.1% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.30 | $36.50 | +3.4% | -0.8% | +4.6% | +11.2% | -9.1% | -3.0% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.90 | $37.30 | +1.1% | -1.1% | -6.6% | +1.8% | -1.7% | +3.2% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.50 | $37.10 | +1.6% | +6.3% | +1.8% | -1.3% | +0.3% | -4.3% |
| Oct 13 | Dawson James | Downgrade | Buy → Neutral | — | $27.10 | $26.30 | -3.0% | -1.5% | +7.9% | -1.0% | +0.0% | -2.5% |
No insider trades available.
NT 10-Q
!! High
ProPhase Labs, Inc. -- Late Quarterly Report -- Distress Signal
May 15
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
Periph Therapeutics' delayed annual report filing suggests financial or operational distress, requiring immediate investor scrutiny of balance sheet health, cash position, and management changes before further investment decisions.
Mar 27
8-K · 8.01
!! High
ProPhase Labs, Inc. -- 8-K 8.01: Material Event / Announcement
ProPhase Labs initiated a strategic process to sell or partner its BE-Smart esophageal cancer diagnostic test, potentially unlocking value from its clinical-stage assets for shareholders.
Feb 13
8-K · 8.01
!! High
ProPhase Labs, Inc. -- 8-K 8.01: Material Event / Announcement
ProPhase Labs announced a February 3, 2026 investor webinar at 4:15pm ET, likely to discuss company developments or financial results with shareholders and analysts.
Feb 13
Valuation
Market Cap
$369K
Enterprise Value
$11.1M
P/E (TTM)
—
Forward P/E
0.01x
PEG Ratio
-0.00x
P/B
0.02x
P/S
0.03x
P/FCF
-0.01x
EV/EBITDA
—
Shares Out
1.9M
Financials (TTM)
Revenue
$4.3M
Net Income
-$14.7M
EBITDA
-$9.2M
Free Cash Flow
-$18.4M
Op Cash Flow
-$17.5M
EPS Basic
$-26.10
EPS Diluted
$-1.47
EPS Forward
$10.40
Gross Margin
31.9%
Op Margin
-415.4%
Net Margin
-339.3%
Balance Sheet
Total Assets
$63.2M
Total Liab.
$55.8M
Total Equity
$7.4M
Cash
$678K
LT Debt
$11.7M
Book Value/Sh
$3.85
Debt/Equity
3.34x
Current Ratio
0.95
Quick Ratio
0.92
Returns & Growth
ROE
-781.5%
ROA
-81.6%
ROIC
-102.6%
Rev Growth YoY
-84.8%
EPS Growth YoY
-166.3%
Price Returns
2W
-16.7%
1M
-23.1%
3M
-33.3%
6M
-95.2%
12M
-97.3%
Technicals
52W High
$6.70
52W Low
$0.07
50d MA
$0.11
200d MA
$1.40
RSI (14)
29.40
ATR (14)
$0.02
Beta
-0.32
Avg Volume
46K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$140.00
High
$140.00
Low
$140.00
Median
$140.00
Data updated apr 27, 2026 11:41pm
· Source: financialmodelingprep.com